Development of New Nanoniosome Carriers for Vorinostat: Evaluation of Anticancer Efficacy In Vitro
- 25 May 2024
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (8) , 2584-2594
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Vorinostat-loaded titanium oxide nanoparticles (anatase) induce G2/M cell cycle arrest in breast cancer cells via PALB2 upregulation3 Biotech, 2020
- Deciphering the Role of Bilayer of a Niosome towards Controlling the Entrapment and Release of DyesChemistrySelect, 2018
- Artemisinin-loaded niosome and pegylated niosome: physico-chemical characterization and effects on MCF-7 cell proliferationJournal of Pharmaceutical Investigation, 2017
- Zinc–Nickel Ferrite Nanoparticles as a Contrast Agent in Magnetic Resonance ImagingApplied Magnetic Resonance, 2016
- Improving Pharmaceutical Characteristics of Curcumin by Alginate/Pectin MicroparticlesPharmaceutical Chemistry Journal, 2016
- Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cellsCarbohydrate Polymers, 2014
- Efficacy comparison of nanoniosomal and pegylated nanoniosomal Cisplatin on A172 cell lineTissue Engineering and Regenerative Medicine, 2014
- mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanismsBreast Cancer Research and Treatment, 2014
- HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMTJournal of Cellular Physiology, 2010
- Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatmentBiochemical Pharmacology, 2007